Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL R SAPER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine

NPI
1891888095
CMS profile
358295
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$867.79

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $742.80 3
Food and Beverage $124.99 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Promius Pharma LLC $720.40 2
Lundbeck LLC $147.39 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL R SAPER

NPI 1891888095 · CMS profile ID 358295

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $867.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $22.4011/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345371 CMS
Lundbeck LLC $124.9911/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345377 CMS
Promius Pharma LLC $574.4002/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097285 CMS
Promius Pharma LLC $146.0001/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097283 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $867.79 4
PY2024 $34.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,643.58 208
PY2024 Principal investigator $778,871.45 258
PY2023 Recipient $188,670.14 42
PY2023 Principal investigator $817,852.03 284
PY2022 Recipient $694.00 1
PY2022 Principal investigator $856,999.67 290
PY2021 Principal investigator $1,105,932.40 208
PY2020 Principal investigator $729,753.82 96
PY2019 Recipient $20,043.40 4
PY2019 Principal investigator $688,115.98 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

326 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $942.50 12/31/2023 Non-covered Recipient Entity
MI HEADACHE & NEUROLOGICAL INSTITUTE
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 998413225
Principal investigator 1 ABBVIE INC. $927.00 12/31/2023 Non-covered Recipient Entity
MI HEADACHE & NEUROLOGICAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998413227
Recipient PFIZER INC. $1,268.15 12/27/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045897043
Recipient PFIZER INC. $15,163.90 12/27/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1045958913
Recipient PFIZER INC. $812.00 12/27/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046136617
Recipient PFIZER INC. $1,692.05 12/27/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046271361
Recipient PFIZER INC. $5,167.05 12/22/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1045955801
Recipient PFIZER INC. $2,498.31 12/21/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046270707
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,455.40 12/19/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811233
Recipient PFIZER INC. $5,551.93 12/14/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046028777
Principal investigator 1 ABBVIE INC. $3,720.00 12/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 998411531
Principal investigator 1 ABBVIE INC. $500.00 12/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998411533
Principal investigator 1 H. Lundbeck A S $1,000.00 12/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059240031
Principal investigator 1 ABBVIE INC. $372.60 12/12/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 998411453
Principal investigator 1 ABBVIE INC. $22.50 12/12/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998411497
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,776.50 12/12/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811195
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,910.80 12/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811183
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $81.00 12/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811281
Recipient PFIZER INC. $750.00 12/07/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046059329
Recipient PFIZER INC. $40.50 12/07/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046273471
Principal investigator 1 ABBVIE INC. $9,406.00 12/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 998409373
Principal investigator 1 ABBVIE INC. $5,891.15 12/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998409375
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,205.00 11/30/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811095
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,154.25 11/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811269
Principal investigator 1 PFIZER INC. $16,784.60 11/24/2023 Non-covered Recipient Entity
1
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046177767
Principal investigator 1 PFIZER INC. $609.00 11/24/2023 Non-covered Recipient Entity
1
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046186141
Principal investigator 1 PFIZER INC. $1,310.72 11/22/2023 Non-covered Recipient Entity
1
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046212651
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,461.80 11/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811243
Principal investigator 1 H. Lundbeck A S $1,618.52 11/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059239515
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,873.15 11/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811207
Principal investigator 1 H. Lundbeck A S $6,500.00 11/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
EPTINEZUMAB IN PARTICIPANTS WITH EPISODIC CLUSTER HEADACHE (ALLEVIATE) No dispute reported 06/30/2026 1059239417
Principal investigator 1 PFIZER INC. $3,456.34 11/16/2023 Non-covered Recipient Entity
1
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045970875
Principal investigator 1 PFIZER INC. $2,892.03 11/16/2023 Non-covered Recipient Entity
1
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046011391
Principal investigator 1 PFIZER INC. $4,506.08 11/16/2023 Non-covered Recipient Entity
1
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046034163
Principal investigator 1 ABBVIE INC. $5,000.00 11/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998408079
Principal investigator 1 ABBVIE INC. $808.65 11/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 998408081
Principal investigator 1 PFIZER INC. $658.80 11/09/2023 Non-covered Recipient Entity
1
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046109871
Principal investigator 1 ABBVIE INC. $75.00 11/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 998407077
Principal investigator 1 ABBVIE INC. $2,910.00 11/07/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998407009
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,873.15 11/07/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811169
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,546.00 11/02/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811131
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $639.90 11/02/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811147
Principal investigator 1 H. Lundbeck A S $33.75 10/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059239163
Principal investigator 1 H. Lundbeck A S $6,100.00 10/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB No dispute reported 06/30/2026 1059239125
Principal investigator 1 H. Lundbeck A S $3,332.96 10/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB No dispute reported 06/30/2026 1059239130
Principal investigator 1 H. Lundbeck A S $3,332.96 10/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB No dispute reported 06/30/2026 1059239135
Principal investigator 1 H. Lundbeck A S $6,100.00 10/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB No dispute reported 06/30/2026 1059239141
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 10/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811071
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,583.65 10/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811257
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 10/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035812681
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 10/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035813107
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 10/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035813119
Recipient PFIZER INC. $1,250.00 10/19/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045895719
Recipient PFIZER INC. $1,000.00 10/19/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046102597
Recipient PFIZER INC. $4,970.34 10/19/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046102785
Recipient PFIZER INC. $2,186.03 10/19/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046121149
Recipient PFIZER INC. $25,693.70 10/19/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046131145
Recipient PFIZER INC. $837.50 10/19/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046141603
Principal investigator 1 ABBVIE INC. $1,000.00 10/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998404423
Principal investigator 1 ABBVIE INC. $630.00 10/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998404425
Principal investigator 1 ABBVIE INC. $40.50 10/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998404427
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,240.30 10/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811219
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 10/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811293
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 10/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035812669
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 10/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035813083
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 10/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035813095
Principal investigator 1 H. Lundbeck A S $10,000.00 10/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1059238981
Principal investigator 1 H. Lundbeck A S $3,000.00 10/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1059238987
Recipient PFIZER INC. $7,031.94 10/12/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1045922723
Recipient PFIZER INC. $202.50 10/12/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046212635
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $743.00 10/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811059
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,025.00 10/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811083
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,486.00 10/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811109
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,410.00 10/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811121
Principal investigator 1 ABBVIE INC. $8,852.25 10/05/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998402501
Recipient PFIZER INC. $958.03 10/05/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046024777
Recipient PFIZER INC. $5,381.39 10/05/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046302625
Principal investigator 1 ABBVIE INC. $2,025.00 10/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 998401843
Principal investigator 1 ABBVIE INC. $3,028.32 10/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998401907
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 10/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811045
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,295.55 10/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811157
Principal investigator 1 H. Lundbeck A S $122.20 09/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1059238387
Recipient PFIZER INC. $500.00 09/26/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046014497
Recipient PFIZER INC. $2,961.29 09/26/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046034149
Recipient PFIZER INC. $337.50 09/26/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046074505
Principal investigator 1 H. Lundbeck A S $1,000.00 09/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1059238333
Recipient PFIZER INC. $3,417.86 09/21/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045956789
Recipient PFIZER INC. $11,478.37 09/21/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046177707
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,784.30 09/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810971
Principal investigator 1 ABBVIE INC. $1,984.50 09/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998400175
Principal investigator 1 H. Lundbeck A S $1,067.04 09/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1059238201
Principal investigator 1 H. Lundbeck A S $893.44 09/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1059238195
Principal investigator 1 H. Lundbeck A S $1,002.92 09/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059238189
Recipient PFIZER INC. $202.50 09/14/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1045999707
Recipient PFIZER INC. $6,923.30 09/14/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046032001
Principal investigator 1 ABBVIE INC. $521.44 09/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998398437
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,009.20 09/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810911
Principal investigator 1 ABBVIE INC. $1,514.16 09/05/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998398183
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,391.50 09/01/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810777
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 09/01/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810861
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,873.15 09/01/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810885
Principal investigator 1 H. Lundbeck A S $27.00 08/30/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059237823
Recipient PFIZER INC. $40.50 08/30/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1045918939
Recipient PFIZER INC. $500.00 08/30/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046309129
Recipient PFIZER INC. $519.75 08/30/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046310347
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,860.10 08/23/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810983
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 08/23/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811033
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,906.15 08/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810947
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $202.50 08/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811009
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $81.00 08/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811021
Principal investigator 1 ABBVIE INC. $202.50 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998396179
Principal investigator 1 ABBVIE INC. $521.44 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998396193
Principal investigator 1 ABBVIE INC. $630.00 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998396195
Recipient PFIZER INC. $9,927.19 08/17/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046118545
Recipient PFIZER INC. $14,868.00 08/17/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046161317
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811429
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811899
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811911
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811923
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811937
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 08/17/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811949
Principal investigator 1 ABBVIE INC. $10,220.37 08/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998394993
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 08/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810787
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,295.55 08/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810923
Principal investigator 1 ABBVIE INC. $1,514.16 08/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998394333
Principal investigator 1 H. Lundbeck A S $3,037.50 08/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1059237321
Principal investigator 1 H. Lundbeck A S $6,500.00 08/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) No dispute reported 06/30/2026 1059237293
Recipient PFIZER INC. $8,194.70 08/03/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046310361
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 08/01/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810825
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,392.45 08/01/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810875
Principal investigator 1 H. Lundbeck A S $1,618.52 07/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059237139
Principal investigator 1 H. Lundbeck A S $33.75 07/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059237145
Principal investigator 1 PFIZER INC. $1,500.00 07/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045897983
Principal investigator 1 PFIZER INC. $952.90 07/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045948059
Principal investigator 1 PFIZER INC. $500.00 07/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045986172
Principal investigator 1 PFIZER INC. $40.50 07/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046165693
Principal investigator 1 PFIZER INC. $1,969.65 07/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046301809
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 07/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810801
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $545.40 07/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810811
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,919.70 07/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810849
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,808.80 07/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810997
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 07/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811419
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 07/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811837
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 07/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811851
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 07/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811863
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 07/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811875
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 07/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811887
Principal investigator 1 H. Lundbeck A S $1,000.00 07/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
EPTINEZUMAB IN PARTICIPANTS WITH EPISODIC CLUSTER HEADACHE (ALLEVIATE) No dispute reported 06/30/2026 1059236985
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,418.45 07/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810959
Principal investigator 1 ABBVIE INC. $202.50 07/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998391045
Principal investigator 1 PFIZER INC. $1,310.72 07/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045922703
Principal investigator 1 PFIZER INC. $2,160.00 07/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046035395
Principal investigator 1 PFIZER INC. $11,325.05 07/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046067895
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,616.65 07/11/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810935
Principal investigator 1 ABBVIE INC. $8,561.25 07/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998389391
Principal investigator 1 PFIZER INC. $1,296.00 07/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1045999781
Principal investigator 1 PFIZER INC. $500.00 07/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046067775
Principal investigator 1 PFIZER INC. $32,249.72 07/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046191075
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 07/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810837
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,231.90 07/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810899
Principal investigator 1 ABBVIE INC. $4,376.99 07/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998389209
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,398.15 06/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810753
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 06/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810765
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 06/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811407
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 06/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811803
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 06/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811815
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 06/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811826
Principal investigator 1 ABBVIE INC. $405.00 06/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998387953
Principal investigator 1 PFIZER INC. $1,000.00 06/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045946737
Principal investigator 1 PFIZER INC. $8,178.55 06/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046035415
Principal investigator 1 PFIZER INC. $243.00 06/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046091547
Principal investigator 1 PFIZER INC. $958.03 06/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046165109
Principal investigator 1 ABBVIE INC. $700.00 06/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998387773
Principal investigator 1 H. Lundbeck A S $27.00 06/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059236239
Principal investigator 1 H. Lundbeck A S $3,628.19 06/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059236245
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 06/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810739
Principal investigator 1 PFIZER INC. $2,186.03 06/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045889831
Principal investigator 1 PFIZER INC. $4,320.00 06/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046257975
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,264.90 06/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810369
Principal investigator 1 PFIZER INC. $4,082.85 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046214305
Principal investigator 1 PFIZER INC. $243.00 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046258849
Principal investigator 1 PFIZER INC. $13,787.55 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046260387
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810157
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $743.00 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810169
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $87.76 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810243
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,205.00 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810257
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,648.95 06/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810333
Principal investigator 1 ABBVIE INC. $4,418.63 06/07/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998385591
Principal investigator 1 H. Lundbeck A S $27.00 06/07/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059236049
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,807.35 05/30/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810133
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 05/30/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810423
Recipient PFIZER INC. $18,568.02 05/25/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046076553
Recipient PFIZER INC. $9,943.65 05/25/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046092371
Recipient PFIZER INC. $40.50 05/25/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046185903
Recipient PFIZER INC. $2,600.00 05/25/2023 Covered Recipient Physician A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046204681
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811393
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811789
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $705.85 05/24/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810395
Recipient PFIZER INC. $3,156.23 05/18/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045978727
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,681.95 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810379
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811381
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811693
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811705
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811719
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811731
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811743
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811755
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811767
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 05/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811779
Principal investigator 1 H. Lundbeck A S $750.00 05/11/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059235763
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 05/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810181
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,455.40 05/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810345
Principal investigator 1 ABBVIE INC. $7,971.38 05/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998380771
Recipient PFIZER INC. $7,632.00 05/04/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1045936747
Recipient PFIZER INC. $500.00 05/04/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1045988185
Recipient PFIZER INC. $337.50 05/04/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046131131
Recipient PFIZER INC. $371.25 05/04/2023 Covered Recipient Physician A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046337105
Principal investigator 1 H. Lundbeck A S $40.50 05/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059235531
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $121.50 05/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810221
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 05/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810321
Principal investigator 1 ABBVIE INC. $183.57 04/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998379873
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,272.60 04/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810408
Principal investigator 1 ABBVIE INC. $1,350.00 04/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 998379031
Principal investigator 1 ABBVIE INC. $700.00 04/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998379217
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 04/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810119
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811371
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811599
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811611
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811623
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811635
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811647
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811659
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811671
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 04/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811683
Recipient PFIZER INC. $3,194.71 04/13/2023 Covered Recipient Physician PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045898447
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 04/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810193
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,621.65 04/13/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810357
Principal investigator 1 H. Lundbeck A S $40.50 04/07/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059235029
Principal investigator 1 H. Lundbeck A S $750.00 04/07/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1059235035
Principal investigator 1 H. Lundbeck A S $27.00 04/07/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059235041
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $200.00 04/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810093
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $440.40 04/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810105
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $140.40 04/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810145
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $345.20 04/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 04/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810233
Principal investigator 1 ABBVIE INC. $3,875.25 03/30/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998376013
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $10,293.34 03/29/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046046253
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 03/29/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809811
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,205.30 03/29/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810069
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,391.50 03/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809859
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $705.85 03/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810009
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,456.80 03/21/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810021
Principal investigator 1 H. Lundbeck A S $5,331.35 03/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059234461
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,461.80 03/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809971
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 03/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811356
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 03/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811575
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 03/14/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811589
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $600.75 03/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046111173
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $5,037.85 03/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046318253
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 03/08/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809761
Principal investigator 1 ABBVIE INC. $4,077.75 03/02/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998372193
Principal investigator 1 H. Lundbeck A S $54.00 03/01/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059234221
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,711.90 02/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809801
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 02/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809825
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,161.25 02/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810055
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 02/28/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810648
Principal investigator 1 Amgen Inc. $500.00 02/24/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Medication Overuse Headache Study (MOH)_ No dispute reported 06/30/2026 1029651113
Principal investigator 1 Amgen Inc. $500.00 02/24/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 1029657995
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $40.50 02/23/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1045963055
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $750.00 02/23/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046035381
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,095.45 02/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809789
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,295.05 02/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809871
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,295.55 02/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810033
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811341
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/22/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811561
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,196.57 02/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1045976643
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $4,434.88 02/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046184291
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $14,257.54 02/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046330367
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,820.00 02/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809835
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,744.90 02/16/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809983
Principal investigator 1 Amgen Inc. $6,644.40 02/15/2023 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL I
Erenumab (EMBRACE) No dispute reported 06/30/2026 1029650677
Principal investigator 1 Amgen Inc. $16,611.00 02/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1029656377
Principal investigator 1 Amgen Inc. $13,288.80 02/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 1029658001
Principal investigator 1 H. Lundbeck A S $1,186.31 02/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059233771
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811331
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/15/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811549
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811317
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811501
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811513
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811527
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 02/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811539
Principal investigator 1 ABBVIE INC. $9,918.75 02/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998369877
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,250.00 02/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046318165
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $6,268.10 02/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046332905
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,873.15 02/09/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809941
Principal investigator 1 ABBVIE INC. $1,564.32 02/02/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998368629
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,487.70 02/02/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809749
Principal investigator 1 H. Lundbeck A S $3,878.28 01/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059233475
Principal investigator 1 H. Lundbeck A S $1,581.32 01/27/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1059233479
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $10,397.75 01/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1046011377
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $16,227.45 01/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046141869
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $803.25 01/26/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1046203497
Principal investigator 1 H. Lundbeck A S $750.00 01/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059233355
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,621.65 01/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810045
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 01/25/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035810081
Principal investigator 1 Amgen Inc. $6,320.00 01/24/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1029656371
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,167.30 01/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809847
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,424.15 01/20/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809995
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 01/19/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811305
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 01/19/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811441
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 01/19/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811453
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 01/19/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811465
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 01/19/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811477
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $698.25 01/19/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035811489
Principal investigator 1 H. Lundbeck A S $54.00 01/18/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059233153
Principal investigator 1 Eli Lilly and Company $399.59 01/13/2023 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 1038118011
Principal investigator 1 ABBVIE INC. $500.00 01/12/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998366181
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,250.00 01/12/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046014485
Principal investigator 1 H. Lundbeck A S $27.00 01/11/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1059233113
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,679.60 01/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809775
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,847.85 01/10/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809957
Principal investigator 1 Eli Lilly and Company $92,866.00 01/06/2023 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 1038111877
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $340.40 01/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809883
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 01/06/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1035809931
Principal investigator 1 H. Lundbeck A S $3,892.39 01/04/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1059232853
Principal investigator 1 ABBVIE INC. $4,894.50 01/03/2023 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 998363579